<DOC>
	<DOCNO>NCT00241410</DOCNO>
	<brief_summary>Safety tolerability different dose combination MPL grass pollen allergen identify high combination MPL grass pollen allergen safe . Pharmacodynamics efficacy MPL grass pollen allergen .</brief_summary>
	<brief_title>Safety , Immunological Effect Efficacy Combined Application MPL Grass Pollen Allergen</brief_title>
	<detailed_description>Objective trial demonstrate safety tolerability different dose combination MPL grass pollen allergen identify high combination MPL grass pollen allergen safe . Other objective investigate pharmacodynamics efficacy MPL grass pollen allergen .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Hypersensitivity , Immediate</mesh_term>
	<criteria>Male female subject , 18 65 year . BMI 18 32 kg/m² . Positive skin prick test ( wheal &gt; 4mm ) grass pollen allergen extract . Specific IgE grass pollen allergen RAST ( equivalent test ) ≥ class 2 . Women childbearing potential must use medically acceptable method birth control negative βHCG pregnancy test result screen Day 1 predose . Male subject must also agree use double barrier method contraception study . In opinion investigator , subject able understand verbal write instruction competent follow instruction . Subjects must read , understand , sign , date write informed consent form Positive human immunodeficiency virus ( HIV ) test , acute chronic hepatitis B/C ( except vaccination titer ) . Positive drug screen . Positive alcohol breath test . Known suspected drug alcohol abuse . History clinically significant cardiovascular ( especially heart failure pulmonary insufficiency ) , pulmonary ( except asthma ) , hepatic , renal , gastrointestinal , hematologic , endocrine , dermatological , metabolic disease within last 2 year . A clinically significant disease define disease , opinion investigator , may either put subject risk participation trial disease may influence result trial subject 's eligibility participate trial . Clinically significant abnormality prestudy physical examination , vital sign , electrocardiogram ( ECG ) , laboratory test ; acute illness within 7 day screen visit . History allergy allseason allergen / history allergy seasonal allergen grass pollen might interfere period trial conduct History major psychiatric disorder schizophrenia , psychotic symptomatology , major depressive disorder , suicide attempt within past 5 year ; history alcohol drug abuse within past year ; history evidence progressive central nervous system ( CNS ) disease , lesion , encephalopathy . History malignancy within past 2 year ; exception basal cell carcinoma . Acute subacute atopic dermatitis . Periodontitis , gingivitis , gingival bleeding mucosal disorder oral cavity plan tooth extraction course study . Secondary change reactive organ ( e.g. , emphysema , bronchiectasis ) . Autoimmune disease ( e.g. , liver , kidney , thyroid , nervous system ) rheumatoid disease . Immunodeficiencies ( e.g. , immunosuppressive agent ) . Therapy βblockers . Therapy antihistamines less three day prior Day 1 . Therapy corticosteroid ( except hormonal contraceptive ) four week prior Day 1 ( exception local steroid , must terminate three day prior Day 1 ) . Vaccinations last three month . Unable comply recommend therapyfree interval specify medication prior skin prick test . Current disease pathogenesis interfere immune response diseases medication give , could influence result study . Acute chronic infection . Already undergone hyposensitization therapy grass pollen allergen within last three year . Use MPLcontaining product within last 12 month allergy / hypersensitivity MPL . Pregnancy breastfeed . Use investigational drug medical device within 30 day prior screen visit . A handicap would prevent compliance study procedure proper report adverse event . Subjects smoke 10 cigarette day Subjects unable conduct nasal wash comply nasal challenge test accord instruction investigator Total flow rhinomanometry vehicle solution 40 % low total flow obtain blank measurement ( note : exclusion criterion apply screen visit nasal challenge test perform Day 1 predose ) In opinion investigator , unable complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Specific Immunotherapy</keyword>
	<keyword>Sublingual Immunotherapy</keyword>
</DOC>